Clinical Experience of S-1 and Oxaliplatin (SOX) as the First-Line Chemotherapy for Metastatic/Recurrent Gastric Cancer
Toyokawa, T.; Tamura, T.; Shibutani, M.; Ohira, G.; Yamazoe, S.; Kimura, K.; Nagahara, H.; Amano, R.; Tanaka, H.; Muguruma, K.; Yashiro, M.; Hirakawa, K.; Ohira, M.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 44(5): 405-408
2017
ISSN/ISBN: 0385-0684 PMID: 28536336 Document Number: 692983
We retrospectively investigated the efficacy and safety of S-1 and oxaliplatin(SOX)as the first-line chemotherapy in patients with metastatic/recurrent gastric cancer. A total of 27 patients who received SOX as the first-line chemotherapy in our hospital were considered for the study. The SOX chemotherapy schedule consisted of 1 course every 3 weeks. S-1 was administered orally, at 80-120mg-body, every day for 14 days. Oxaliplatin was infused at 100mg/m2 on day 1 of each course. The median number of treatment courses was 7. The response rate and disease control rate were 47.6% and 76.2%, respectively. The observed adverse events of Grade 3 or more included neutropenia(33.3%); peripheral neuropathy and anorexia(11.1%); thrombocytopenia(7.4%); and anemia, diarrhea, fatigue, and hypercalcemia(3.7%). The median overall survival was not achieved, and the 1-year survival rate was 63.2%. Therefore, SOX is an effective and feasible first-line chemotherapy that is easily available for ambulatory treatment of patients with metastatic/recurrent gastric cancer.